1. Show article details.

    Marijuana Stock Movers For May 9, 2022

    Benzinga – 4:48 PM ET 05/09/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  2. Show article details.

    Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

    Benzinga – 3:10 PM ET 05/06/2022

    Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

  3. Show article details.

    Meridian Bioscience: Q2 Earnings Insights

    Benzinga – 9:08 AM ET 05/06/2022

      Meridian Bioscience reported its Q2 earnings results on Friday, May 6, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Meridian Bioscience beat estimated earnings by 40.43%, reporting an EPS of $0.66 versus an estimate of $0.47. Revenue was up $25.97 million from the same period last year.

  4. Show article details.

    BRIEF-Meridian Bioscience Reports Record Second Quarter Fiscal 2022 Operating Results

    Reuters – 8:22 AM ET 05/06/2022

    Meridian Bioscience Inc (VIVO): * MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS. * SEES FY ADJUSTED EARNINGS PER SHARE $1.30 TO $1.40. * Q2 REVENUE ROSE 30 PERCENT TO $111.2 MILLION. * SEES CONSOLIDATED FY NET REVENUE $330.0 MILLION TO $345.0 MILLION.

  5. Show article details.

    MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

    PR Newswire – 8:00 AM ET 05/06/2022

    CINCINNATI, May 6, 2022 Meridian Bioscience, Inc. (VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights: Jack Kenny, Chief Executive Officer, commented, "Meridian delivered another strong quarter.

  6. Show article details.

    Earnings Scheduled For May 6, 2022

    Benzinga – 5:13 AM ET 05/06/2022

      ** Brookfield Renewable is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion. ** Tile Shop Holdings is expected to report quarterly earnings at $0.09 per share on revenue of $95.03 million. ** Intercept Pharmaceuticals is projected to report quarterly loss at $0.90 per share on revenue of $90.49 million.

  7. Show article details.

    Cannabis Stock Movers For May 5, 2022

    Benzinga – 4:39 PM ET 05/05/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  8. Show article details.

    Meridian Bioscience's Earnings: A Preview

    Benzinga – 1:22 PM ET 05/05/2022

    Meridian Bioscience is set to give its latest quarterly earnings report on Friday, 2022-05-06. Analysts estimate that Meridian Bioscience will report an earnings per share of $0.47. Meridian Bioscience bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

  9. Show article details.

    Bullish Sentiment Across The Cannabis Space - Check Full Movers For May 4, 2022

    Benzinga – 4:36 PM ET 05/04/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  10. Show article details.

    BRIEF-Meridian Acquires EUPROTEIN To Further Expand Recombinant Protein Capabilities

    Reuters – 9:18 AM ET 05/02/2022

    Meridian Bioscience Inc (VIVO): * MERIDIAN ACQUIRES EUPROTEIN TO FURTHER EXPAND RECOMBINANT PROTEIN CAPABILITIES. * Meridian Bioscience Inc (VIVO) - HAS ACQUIRED, THROUGH SUBSIDIARY MERIDIAN LIFE SCIENCE, INC, SUBSTANTIALLY ALL OF ASSETS OF EUPROTEIN INC Source text for Eikon: Further company coverage:

  11. Show article details.

    Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

    PR Newswire – 8:47 AM ET 05/02/2022

    CINCINNATI, Ohio, May 2, 2022  Meridian Bioscience (VIVO), Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc.  The transaction closed on April 30, 2022.

  12. Show article details.

    Marijuana Stock Movers For April 26, 2022

    Benzinga – 4:33 PM ET 04/26/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  13. Show article details.

    Cannabis Stock Gainers And Losers From April 22, 2022

    Benzinga – 4:55 PM ET 04/22/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  14. Show article details.

    Cannabis Stock Gainers And Losers From April 7, 2022

    Benzinga – 4:31 PM ET 04/07/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  15. Show article details.

    Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter

    PR Newswire – 8:35 AM ET 04/07/2022

    CINCINNATI, April 7, 2022 Meridian Bioscience, Inc. (VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary net revenues results for its second quarter of fiscal 2022.

  16. Show article details.

    Meridian Bioscience Earnings Perspective: Return On Capital Employed

    Benzinga – 10:14 AM ET 04/01/2022

    According to Benzinga Pro, during Q1, Meridian Bioscience earned $15.34 million, a 130.43% increase from the preceding quarter. Earnings data without context is not clear and can be difficult to base trading decisions on. It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool.

  17. Show article details.

    Meridian Bioscience Launches Lyo-Ready™ qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection

    PR Newswire – 2:37 PM ET 03/29/2022

    CINCINNATI, March 29, 2022 Meridian Bioscience, Inc. (VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy – enabling the earliest detection of cancer using non-invasive liquid biopsy.

  18. Show article details.

    Marijuana Stock Movers For March 16, 2022

    Benzinga – 6:36 PM ET 03/16/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  19. Show article details.

    Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer

    PR Newswire – 9:00 AM ET 02/21/2022

    CINCINNATI, Ohio, Feb. 21, 2022 Meridian Bioscience, Inc. (VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Andy Kitzmiller joined Meridian Bioscience (VIVO) as Executive Vice President and Chief Financial Officer, reporting directly to CEO Jack Kenny. He will oversee the global finance organization and financial activities, including accou...

  20. Show article details.

    Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits

    PR Newswire – 9:05 AM ET 02/16/2022

    CINCINNATI, Feb. 16, 2022  Meridian Bioscience, Inc. (VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Magellan Diagnostics resumed manufacturing and distribution of their LeadCare® II test kits. The Magellan quality management system identified discrepancies in the performance of LeadCare test kits.

Page:

Today's and Upcoming Events

  • Aug
    04

    VIVO to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    06

    VIVO announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.